Danske Bank A S Makes New Investment in Natera, Inc. $NTRA

Danske Bank A S acquired a new stake in Natera, Inc. (NASDAQ:NTRA) during the 2nd quarter, Holdings Channel.com reports. The firm acquired 61,302 shares of the medical research company’s stock, valued at approximately $16,640,000.

Other large investors have also recently added to or reduced their stakes in the company. Integrated Wealth Concepts LLC raised its stake in shares of Natera by 6.6% in the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after acquiring an additional 96 shares during the period. NewEdge Advisors LLC increased its holdings in shares of Natera by 68.3% in the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock valued at $644,000 after acquiring an additional 1,847 shares during the last quarter. Focus Partners Wealth lifted its stake in Natera by 8.6% during the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after purchasing an additional 474 shares during the last quarter. Sivia Capital Partners LLC bought a new position in Natera during the second quarter worth $298,000. Finally, WINTON GROUP Ltd acquired a new position in Natera in the second quarter worth $558,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, insider Solomon Moshkevich sold 3,410 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $265.58, for a total transaction of $905,627.80. Following the completion of the sale, the insider owned 129,019 shares of the company’s stock, valued at $34,264,866.02. This represents a 2.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Roelof Botha sold 78,000 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $220.31, for a total value of $17,184,180.00. Following the transaction, the director owned 1,076,198 shares of the company’s stock, valued at approximately $237,097,181.38. The trade was a 6.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 181,045 shares of company stock worth $41,330,968 over the last ninety days. Insiders own 5.05% of the company’s stock.

Analyst Ratings Changes

NTRA has been the topic of a number of research reports. Robert W. Baird set a $348.00 target price on shares of Natera in a report on Friday, August 7th. Wall Street Zen lowered shares of Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. JPMorgan Chase & Co. lifted their price target on shares of Natera from $315.00 to $360.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Zacks Research raised shares of Natera from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Finally, Wells Fargo & Company boosted their price target on shares of Natera from $220.00 to $284.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Natera has an average rating of “Moderate Buy” and an average price target of $319.38.

Natera Stock Down 0.1%

Shares of Natera stock opened at $324.84 on Friday. The company has a 50-day simple moving average of $271.84 and a 200 day simple moving average of $228.67. The stock has a market capitalization of $46.82 billion, a P/E ratio of -238.85 and a beta of 1.51. Natera, Inc. has a 12-month low of $157.43 and a 12-month high of $333.56.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. During the same period in the prior year, the business earned ($0.74) earnings per share. Natera’s quarterly revenue was up 37.7% on a year-over-year basis. On average, equities analysts anticipate that Natera, Inc. will post -1.02 earnings per share for the current year.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.